Impax continues to invest in order to provide the highest level of research and development, manufacturing, and customer service. Our quality assurance team works closely with our suppliers to ensure purity, consistency, and quality of products, and we strive to bring value to our customers with innovative products in key therapeutic areas.
One of our strengths is our experience in developing controlled-release products. We have developed a number of different controlled-release delivery technologies that can be utilized with a variety of oral dosage forms and drugs. We believe that these technologies are flexible and can be applied to develop a variety of pharmaceutical products, both generic and branded.
Our generic product development strategy is based on a combination of speed to filing and a legal strategy primarily predicated upon non-infringement of established brand name pharmaceuticals. We are focused on targeting first-to-file or first-to-market product opportunities.
Our brand product development strategy is based on targeting significant unmet needs in the Central Nervous System (CNS) market. We typically focus on improving the clinical utility of existing molecules utilizing our proprietary technologies, following a 505(b)(2) regulatory pathway of approval. The goal is to utilize our expertise in drug-delivery technology to offer innovative products that enhance the care of patients with CNS disorders.